A new phase 3 study has examined retatrutide in adults with moderate-to-severe obstructive sleep apnoea and overweight or obesity. The authors report changes in the apnoea-hypopnoea index after 80 weeks in two randomised, placebo-controlled trials. This is evidence about an investigational medicine in defined clinical studies, not evidence about Peptra Labs research reagents.
Contents
What did the retatrutide sleep apnoea study test?
The report combines two trials named TRIUMPH-1-OSA and TRIUMPH-2-OSA. The first enrolled adults without type 2 diabetes and the second enrolled adults with type 2 diabetes. Both trials included moderate-to-severe obstructive sleep apnoea and a body-mass index of at least 27. Participants were assigned to once-weekly retatrutide at 4, 9 or 12 mg, or to placebo. The study was double-blind and randomised.
The primary outcome was the change in the apnoea-hypopnoea index, or AHI. AHI is the average number of apnoeas and hypopnoeas recorded per hour of sleep. The authors assessed the main comparison at 80 weeks, using a prespecified analysis that handled events occurring after randomisation. They also reported intention-to-treat results.
What changes did the authors report?
TRIUMPH-1-OSA randomised 243 participants. The baseline mean AHI was 58.6 events per hour. At 80 weeks, the reported mean AHI changes with retatrutide were minus 22.9 events per hour at 4 mg, minus 34.3 at 9 mg and minus 31.7 at 12 mg. The placebo change was minus 9.9 events per hour. The differences versus placebo were therefore minus 13.0, minus 24.4 and minus 21.9 events per hour, respectively, under the hybrid-treatment estimand.
TRIUMPH-2-OSA randomised 448 participants, with a baseline mean AHI of 55.9 events per hour. The corresponding changes with retatrutide were minus 19.2, minus 24.7 and minus 25.4 events per hour at 4, 9 and 12 mg. The placebo change was minus 10.3. The reported differences versus placebo were minus 8.9, minus 14.4 and minus 15.1 events per hour. The confidence intervals and the intention-to-treat analysis are reported in the original paper.
What else did the trials measure?
Change in body weight was a key secondary end point. Under the treatment-regimen estimand, mean percentage changes with retatrutide ranged from minus 12.5% to minus 22.2% in TRIUMPH-1-OSA and from minus 12.1% to minus 18.5% in TRIUMPH-2-OSA. The placebo groups showed changes of minus 4.8% and minus 5.6%. The most common adverse events were gastrointestinal, according to the abstract.
The study therefore links two clinical measurements in a specific population: sleep-related breathing events and body weight. It does not show that every person with sleep apnoea would experience the same change. It also does not establish the effect of a research peptide sold for laboratory work. Retatrutide is investigational in this report, and pharmaceutical authorisation, where applicable, belongs to a specific authorised product and indication, not to a research reagent.
How should this clinical evidence be interpreted?
The design is stronger than an uncontrolled observation because it was randomised, blinded and placebo-controlled. Even so, interpretation depends on the enrolled population, the trial protocol, the estimand, the duration and the outcomes selected. The abstract does not provide every detail needed to judge all secondary outcomes, subgroup effects or longer-term questions. The results should be read as the authors’ findings from TRIUMPH-1-OSA and TRIUMPH-2-OSA, not as general treatment advice.
For research readers, the useful distinction is between a clinical trial result and a catalogue description. This paper reports a controlled clinical evaluation of an investigational triple agonist. It does not provide instructions for human use, dosing advice outside the trial, or evidence about the identity, purity or testing of any Peptra Labs lot. Those questions require separate primary documentation and should not be inferred from this study.
Related on Peptra Labs
For background, see the retatrutide research guide, the retatrutide catalogue page and the receptor comparison research article. These pages provide context, but they do not change the evidence level of the clinical trial.
References
- Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. New England Journal of Medicine. 2026. PubMed. ClinicalTrials.gov: NCT05929066 and NCT05929079.
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.
